Have Analysts Now Turned Cautious On Schweitzer-Mauduit International, Inc. (SWM), ZIOPHARM Oncology, Inc. (ZIOP)?

Schweitzer-Mauduit International, Inc. (NYSE:SWM) recent rally took place on significantly less volume which dipped to nearly 0.27 million contracts on 08-Feb-19 versus its daily average of 254.65 million. The first sale was made at $31.01 but later the stock became weaker, and closed with a gain of 4.4%. It was last traded at $32.54 apiece.

Schweitzer-Mauduit International, Inc. (SWM): Outperform Candidate With 22.93% Upside Potential

Schweitzer-Mauduit International, Inc. is maintained at an average outperform rating by 2 stock analysts, and there are at least 3.45% of shares outstanding that are currently legally short sold. The shares went up by 16.3% in value last month. Year-to-date it jumped 29.9%. Analysts are turning out to be more optimistic than before, with 1 of analysts who cover Schweitzer-Mauduit International, Inc. (NYSE:SWM) advice adding it to buy candidate list. Wall Street experts also assign a $40 price target on Schweitzer-Mauduit International, Inc., pointing towards a 22.93% rally from current levels. The stock is trading for about -28.45% less than its 52-week high.

Schweitzer-Mauduit International, Inc. Reports -1.19% Sales Growth

Schweitzer-Mauduit International, Inc. (SWM) remained unsuccessful in beating the consensus-estimated $0.81 as it actually earned $0.77 per share in its last reported financial results. Revenue, on the other hand, scored -1.19% growth from the previous quarter, coming up with $266.8 million.

SWM Adds 2.33% In A Week

This company shares (SWM) so far managed to recover 33.63% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 2.58% while widening the period to a month, volatility was 2.5%. The share price has already crossed its 20 days moving average, floating at a distance of 5.51% and sits 14.11% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 2.33% gains and is down by -12.08% compared with its 200-day moving average of $34.04. Also, Schweitzer-Mauduit International, Inc. (SWM) needs to overturn a -22.28% decrease it experienced over the past twelve months.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Consensus Call At 2.8

As regular trading ended, ZIOPHARM Oncology, Inc. (ZIOP) stock brought in a $0.1 rise to $2.38. The day started at a price of $2.25 but then traded as high as $2.39 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2.8. ZIOPHARM Oncology, Inc. is given 0 buy-equivalent recommendations, 0 sells and 1 holds. The company shares sank -52.4% from their peak of $5 and now has a $367.81 million market value of equity.

ZIOPHARM Oncology, Inc. Could Grow 89.08% More

ZIOP’s mean recommendation on Reuter’s scale presents no change from 2.75 thirty days ago to 2.75 now, which indicates a hold consensus from the analyst community. They see ZIOPHARM Oncology, Inc. (ZIOP) price hitting a mean target of $4.5 a share, meaning the stock still has potential that could lift the price another 89.08% . Also, the recent close suggests the stock is underpriced by 131.09% compared to the most bullish target.

ZIOPHARM Oncology, Inc. (ZIOP) Returns 27.27% This Year

The company had seen its current volume reaching at 1.18 million shares in the last trade. That compares with the recent volume average of 2.09 million. At the close of regular trading, its last week’s stock price volatility was 8.29% which for the month reaches 6.2%. ZIOPHARM Oncology, Inc. dipped to as low as $2.23 throughout the day and has returned 27.27% in this year. At one point in the past year, the shares traded as low as $1.56 but has recovered 52.56% since then.